{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:21:27Z","timestamp":1769091687295,"version":"3.49.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13231-4","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T09:06:11Z","timestamp":1733389571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radioresistance-related gene signatures identified by transcriptomics characterize the prognosis and immune landscape of pancreatic cancer patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Dandan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisha","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Litao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"13231_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","DOI":"10.3322\/caac.21763"},{"issue":"1","key":"13231_CR2","doi-asserted-by":"publisher","first-page":"16425","DOI":"10.1038\/s41598-020-73525-y","volume":"10","author":"A Bengtsson","year":"2020","unstructured":"Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10(1):16425. https:\/\/doi.org\/10.1038\/s41598-020-73525-y.","journal-title":"Sci Rep"},{"issue":"4","key":"13231_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3978\/j.issn.2078-6891.2012.029","volume":"3","author":"NK Malik","year":"2012","unstructured":"Malik NK, May KS, Chandrasekhar R, Wee W, Flaherty L, Iyer R, et al. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol. 2012;3(4):326\u201334. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2012.029.","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"13231_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","volume":"155","author":"M Bockhorn","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of pancreatic surgery (ISGPS). Surgery. 2014;155(6):977\u201388. https:\/\/doi.org\/10.1016\/j.surg.2014.02.001.","journal-title":"Surgery"},{"key":"13231_CR5","doi-asserted-by":"publisher","unstructured":"Pajewska M, Partyka O, Czerw A, Deptala A, Cipora E, Gaska I, et al. Management of metastatic pancreatic Cancer-comparison of global guidelines over the last 5 years. Cancers (Basel). 2023;15(17). https:\/\/doi.org\/10.3390\/cancers15174400.","DOI":"10.3390\/cancers15174400"},{"issue":"3","key":"13231_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7150\/ijms.3635","volume":"9","author":"R Baskar","year":"2012","unstructured":"Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193\u20139. https:\/\/doi.org\/10.7150\/ijms.3635.","journal-title":"Int J Med Sci"},{"issue":"17","key":"13231_CR7","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in patients with locally Advanced Pancreatic Cancer Controlled after 4 months of Gemcitabine with or without Erlotinib: the LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844\u201353. https:\/\/doi.org\/10.1001\/jama.2016.4324.","journal-title":"JAMA"},{"issue":"9","key":"13231_CR8","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"B Chauffert","year":"2008","unstructured":"Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouch\u00e9 O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD\/SFRO study. Ann Oncol. 2008;19(9):1592\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdn281.","journal-title":"Ann Oncol"},{"key":"13231_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13014-014-0312-5","volume":"10","author":"Z Wang","year":"2015","unstructured":"Wang Z, Ren ZG, Ma NY, Zhao JD, Zhang Z, Ma XJ, et al. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis. Radiat Oncol. 2015;10:14. https:\/\/doi.org\/10.1186\/s13014-014-0312-5.","journal-title":"Radiat Oncol"},{"issue":"31","key":"13231_CR10","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/jco.2011.34.8904","volume":"29","author":"PJ Loehrer","year":"2011","unstructured":"Loehrer PJ, Sr., Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105\u201312. https:\/\/doi.org\/10.1200\/jco.2011.34.8904.","journal-title":"J Clin Oncol"},{"issue":"10","key":"13231_CR11","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/cncr.32756","volume":"126","author":"LT Tchelebi","year":"2020","unstructured":"Tchelebi LT, Lehrer EJ, Trifiletti DM, Sharma NK, Gusani NJ, Crane CH, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis. Cancer. 2020;126(10):2120\u201331. https:\/\/doi.org\/10.1002\/cncr.32756.","journal-title":"Cancer"},{"key":"13231_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annu Rev Pathol. 2023;18:123\u201348. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-031621-024600.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"13231_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbcan.2017.02.003","volume":"1868","author":"P Seshacharyulu","year":"2017","unstructured":"Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, et al. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2017;1868(1):69\u201392. https:\/\/doi.org\/10.1016\/j.bbcan.2017.02.003.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"13231_CR14","doi-asserted-by":"publisher","first-page":"100903","DOI":"10.1016\/j.ajps.2024.100903","volume":"19","author":"X Sun","year":"2024","unstructured":"Sun X, Wu L, Du L, Xu W, Han M. Targeting the organelle for radiosensitization in cancer radiotherapy. Asian J Pharm Sci. 2024;19(2):100903. https:\/\/doi.org\/10.1016\/j.ajps.2024.100903.","journal-title":"Asian J Pharm Sci"},{"issue":"6","key":"13231_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/s12276-021-00640-9","volume":"53","author":"T Suwa","year":"2021","unstructured":"Suwa T, Kobayashi M, Nam JM, Harada H. Tumor microenvironment and radioresistance. Exp Mol Med. 2021;53(6):1029\u201335. https:\/\/doi.org\/10.1038\/s12276-021-00640-9.","journal-title":"Exp Mol Med"},{"key":"13231_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinformatics"},{"issue":"7","key":"13231_CR17","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"13231_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","volume":"173","author":"A Blum","year":"2018","unstructured":"Blum A, Wang P, Zenklusen JC, SnapShot. TCGA-Analyzed tumors. Cell. 2018;173(2):530. https:\/\/doi.org\/10.1016\/j.cell.2018.03.059.","journal-title":"Cell"},{"issue":"8","key":"13231_CR19","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71. https:\/\/doi.org\/10.1093\/nar\/gkv1507.","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"13231_CR20","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","volume":"23","author":"S Davis","year":"2007","unstructured":"Davis S, Meltzer PS. GEOquery: a bridge between the Gene expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007;23(14):1846\u20137. https:\/\/doi.org\/10.1093\/bioinformatics\/btm254.","journal-title":"Bioinformatics"},{"issue":"6","key":"13231_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/bioinformatics\/btp053","volume":"25","author":"DJ McCarthy","year":"2009","unstructured":"McCarthy DJ, Smyth GK. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics. 2009;25(6):765\u201371. https:\/\/doi.org\/10.1093\/bioinformatics\/btp053.","journal-title":"Bioinformatics"},{"issue":"5","key":"13231_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"issue":"4","key":"13231_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385\u201395. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3.","journal-title":"Stat Med"},{"key":"13231_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor infiltrating Immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_12.","journal-title":"Methods Mol Biol"},{"issue":"10","key":"13231_CR25","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0136-1.","journal-title":"Nat Med"},{"issue":"1","key":"13231_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019.","journal-title":"Cell Rep"},{"key":"13231_CR27","doi-asserted-by":"publisher","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6). https:\/\/doi.org\/10.1093\/bib\/bbab260.","DOI":"10.1093\/bib\/bbab260"},{"issue":"11","key":"13231_CR28","doi-asserted-by":"publisher","first-page":"9727","DOI":"10.18632\/aging.205896","volume":"16","author":"D Wang","year":"2024","unstructured":"Wang D, Luo H, Chen Y, Ou Y, Dong M, Chen J, et al. 14-3-3sigma downregulation sensitizes pancreatic cancer to carbon ions by suppressing the homologous recombination repair pathway. Aging. 2024;16(11):9727\u201352. https:\/\/doi.org\/10.18632\/aging.205896.","journal-title":"Aging"},{"issue":"1","key":"13231_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","volume":"121","author":"E Karamitopoulou","year":"2019","unstructured":"Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer. 2019;121(1):5\u201314. https:\/\/doi.org\/10.1038\/s41416-019-0479-5.","journal-title":"Br J Cancer"},{"issue":"3","key":"13231_CR30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","volume":"44","author":"B Mlecnik","year":"2016","unstructured":"Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of Colorectal Cancer Show Immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698\u2013711. https:\/\/doi.org\/10.1016\/j.immuni.2016.02.025.","journal-title":"Immunity"},{"key":"13231_CR31","doi-asserted-by":"publisher","unstructured":"Shen WT, Song ZG, Zhong X, Huang M, Shen DT, Gao PP et al. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2022;1(3). doi: ARTN e36 https:\/\/doi.org\/10.1002\/imt2.36","DOI":"10.1002\/imt2.36"},{"issue":"6","key":"13231_CR32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"J Lonsdale","year":"2013","unstructured":"Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. Nat Genet. 2013;45(6):580\u20135. https:\/\/doi.org\/10.1038\/ng.2653. The Genotype-Tissue Expression (GTEx) project.","journal-title":"Nat Genet"},{"issue":"3","key":"13231_CR33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4143\/crt.2021.299","volume":"53","author":"KS Kim","year":"2021","unstructured":"Kim KS, Wu HG. Who will benefit from charged-particle therapy? Cancer Res Treat. 2021;53(3):621\u201334. https:\/\/doi.org\/10.4143\/crt.2021.299.","journal-title":"Cancer Res Treat"},{"key":"13231_CR34","doi-asserted-by":"publisher","first-page":"e073995","DOI":"10.1136\/bmj-2022-073995","volume":"383","author":"M Del Chiaro","year":"2023","unstructured":"Del Chiaro M, Sugawara T, Karam SD, Messersmith WA. Advances in the management of pancreatic cancer. BMJ. 2023;383:e073995. https:\/\/doi.org\/10.1136\/bmj-2022-073995.","journal-title":"BMJ"},{"key":"13231_CR35","doi-asserted-by":"publisher","unstructured":"Liu J, Lee P, McGee HM, Chung V, Melstrom L, Singh G, et al. Advances in Radiation Oncology for Pancreatic Cancer: an updated review. Cancers (Basel). 2022;14(23). https:\/\/doi.org\/10.3390\/cancers14235725.","DOI":"10.3390\/cancers14235725"},{"key":"13231_CR36","doi-asserted-by":"publisher","unstructured":"sElkhamisy SA, Valentini C, Lattermann A, Radhakrishna G, Kunzel LA, Lock S, et al. Normo- or hypo-fractionated photon or Proton Radiotherapy in the management of locally Advanced Unresectable Pancreatic Cancer: a systematic review. Cancers (Basel). 2023;15(15). https:\/\/doi.org\/10.3390\/cancers15153771.","DOI":"10.3390\/cancers15153771"},{"key":"13231_CR37","doi-asserted-by":"publisher","unstructured":"Okamoto M, Shiba S, Kobayashi D, Miyasaka Y, Okazaki S, Shibuya K, et al. Carbon-Ion Radiotherapy combined with concurrent chemotherapy for locally advanced pancreatic Cancer: a retrospective Case Series Analysis. Cancers (Basel). 2023;15(10). https:\/\/doi.org\/10.3390\/cancers15102857.","DOI":"10.3390\/cancers15102857"},{"issue":"8","key":"13231_CR38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487\u2013505. https:\/\/doi.org\/10.1038\/s41575-020-0300-1.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"13231_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1):96. https:\/\/doi.org\/10.1186\/s12943-023-01801-2.","journal-title":"Mol Cancer"},{"key":"13231_CR40","doi-asserted-by":"publisher","unstructured":"Kotsafti A, Scarpa M, Castagliuolo I, Scarpa M. Reactive oxygen species and Antitumor immunity-from Surveillance to Evasion. Cancers (Basel). 2020;12(7). https:\/\/doi.org\/10.3390\/cancers12071748.","DOI":"10.3390\/cancers12071748"},{"issue":"8","key":"13231_CR41","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","volume":"25","author":"C Lynch","year":"2024","unstructured":"Lynch C, Pitroda SP, Weichselbaum RR. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024;25(8):e352\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00075-5.","journal-title":"Lancet Oncol"},{"issue":"3","key":"13231_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/ecc.12041","volume":"22","author":"D Vianna","year":"2013","unstructured":"Vianna D, Claro LL, Mendes AA, da Silva AN, Bucci DA, de Sa PT, et al. Infusion of life: patient perceptions of expressive therapy during chemotherapy sessions. Eur J Cancer Care (Engl). 2013;22(3):377\u201388. https:\/\/doi.org\/10.1111\/ecc.12041.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"13231_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41525-021-00200-0","volume":"6","author":"YH Dai","year":"2021","unstructured":"Dai YH, Wang YF, Shen PC, Lo CH, Yang JF, Lin CS, et al. Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy. NPJ Genom Med. 2021;6(1):40. https:\/\/doi.org\/10.1038\/s41525-021-00200-0.","journal-title":"NPJ Genom Med"},{"key":"13231_CR44","doi-asserted-by":"publisher","unstructured":"Piper M, Hoen M, Darragh LB, Knitz MW, Nguyen D, Gadwa J et al. Simultaneous targeting of PD-1 and IL-2Rbetagamma with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer Cell. 2023;41(5):950\u2009\u2013\u200969 e6. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.001","DOI":"10.1016\/j.ccell.2023.04.001"},{"issue":"2","key":"13231_CR45","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","volume":"13","author":"C Falcomata","year":"2023","unstructured":"Falcomata C, Barthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D. Context-specific determinants of the immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Cancer Discov. 2023;13(2):278\u201397. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0876.","journal-title":"Cancer Discov"},{"key":"13231_CR46","doi-asserted-by":"publisher","unstructured":"Deng D, Patel R, Chiang CY, Hou P. Role of the Tumor Microenvironment in regulating pancreatic Cancer Therapy Resistance. Cells. 2022;11(19). https:\/\/doi.org\/10.3390\/cells11192952.","DOI":"10.3390\/cells11192952"},{"key":"13231_CR47","doi-asserted-by":"publisher","unstructured":"Parikh A, Wo JYL, Ryan DP, Clark JW, Nipp RD, Blaszkowsky LS, et al. A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma. J Clin Oncol. 2019;37(4). https:\/\/doi.org\/10.1200\/JCO.2019.37.4_suppl.391.","DOI":"10.1200\/JCO.2019.37.4_suppl.391"},{"issue":"4","key":"13231_CR48","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.ijrobp.2014.03.043","volume":"89","author":"CW Song","year":"2014","unstructured":"Song CW, Park I, Cho LC, Yuan J, Dusenbery KE, Griffin RJ, et al. Is indirect cell death involved in response of tumors to stereotactic radiosurgery and stereotactic body radiation therapy? Int J Radiat Oncol Biol Phys. 2014;89(4):924\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.03.043.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"13231_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijrobp.2015.05.016","volume":"93","author":"CW Song","year":"2015","unstructured":"Song CW, Lee YJ, Griffin RJ, Park I, Koonce NA, Hui S, et al. Indirect Tumor Cell Death after High-Dose Hypofractionated Irradiation: implications for stereotactic body Radiation Therapy and Stereotactic Radiation surgery. Int J Radiat Oncol Biol Phys. 2015;93(1):166\u201372. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.05.016.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"13231_CR50","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/1078-0432.CCR-20-4640","volume":"27","author":"C Xie","year":"2021","unstructured":"Xie C, Duffy AG, Brar G, Fioravanti S, Mabry-Hrones D, Walker M, et al. Correction: Immune Checkpoint Blockade in Combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res. 2021;27(1):358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4640.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"13231_CR51","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic Cancer: Pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386\u2013e4021. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056.","journal-title":"Gastroenterology"},{"issue":"1","key":"13231_CR52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","volume":"12","author":"LL Siu","year":"2006","unstructured":"Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006;12(1):144\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1571.","journal-title":"Clin Cancer Res"},{"key":"13231_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1476-4598-12-81","volume":"12","author":"F Wei","year":"2013","unstructured":"Wei F, Liu Y, Guo Y, Xiang A, Wang G, Xue X, et al. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Mol Cancer. 2013;12:81. https:\/\/doi.org\/10.1186\/1476-4598-12-81.","journal-title":"Mol Cancer"},{"issue":"1","key":"13231_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/1535-7163.MCT-13-0242","volume":"13","author":"JY Zeng","year":"2014","unstructured":"Zeng JY, Sharma S, Zhou YQ, Yao HP, Hu X, Zhang R, et al. Synergistic activities of MET\/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Mol Cancer Ther. 2014;13(1):37\u201348. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0242.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"13231_CR55","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"18","key":"13231_CR56","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"key":"13231_CR57","doi-asserted-by":"publisher","first-page":"107906","DOI":"10.1016\/j.intimp.2021.107906","volume":"98","author":"F Sun","year":"2021","unstructured":"Sun F, Yue TT, Yang CL, Wang FX, Luo JH, Rong SJ, et al. The MAPK dual specific phosphatase (DUSP) proteins: a versatile wrestler in T cell functionality. Int Immunopharmacol. 2021;98:107906. https:\/\/doi.org\/10.1016\/j.intimp.2021.107906.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"13231_CR58","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/bj20082234","volume":"418","author":"KI Patterson","year":"2009","unstructured":"Patterson KI, Brummer T, O\u2019Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009;418(3):475\u201389. https:\/\/doi.org\/10.1042\/bj20082234.","journal-title":"Biochem J"},{"issue":"11","key":"13231_CR59","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1074\/jbc.271.11.6497","volume":"271","author":"Y Chu","year":"1996","unstructured":"Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem. 1996;271(11):6497\u2013501. https:\/\/doi.org\/10.1074\/jbc.271.11.6497.","journal-title":"J Biol Chem"},{"issue":"20","key":"13231_CR60","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.1158\/0008-5472.CAN-13-1385","volume":"73","author":"JM Balko","year":"2013","unstructured":"Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, et al. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 2013;73(20):6346\u201358. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1385.","journal-title":"Cancer Res"},{"issue":"20","key":"13231_CR61","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.yexcr.2013.08.023","volume":"319","author":"Y Liu","year":"2013","unstructured":"Liu Y, Du F, Chen W, Yao M, Lv K, Fu P. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7\/ADR breast cancer cells to doxorubicin. Exp Cell Res. 2013;319(20):3140\u20139. https:\/\/doi.org\/10.1016\/j.yexcr.2013.08.023.","journal-title":"Exp Cell Res"},{"issue":"7","key":"13231_CR62","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/ijc.21570","volume":"118","author":"B Gyorffy","year":"2006","unstructured":"Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, Dietel M, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006;118(7):1699\u2013712. https:\/\/doi.org\/10.1002\/ijc.21570.","journal-title":"Int J Cancer"},{"issue":"24","key":"13231_CR63","doi-asserted-by":"publisher","first-page":"11554","DOI":"10.1158\/0008-5472.CAN-06-1935","volume":"66","author":"MK Nyati","year":"2006","unstructured":"Nyati MK, Feng FY, Maheshwari D, Varambally S, Zielske SP, Ahsan A, et al. Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1\/2 via activation of MKP-1 in response to radiation. Cancer Res. 2006;66(24):11554\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1935.","journal-title":"Cancer Res"},{"key":"13231_CR64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2020.01.037","volume":"483","author":"H Chen","year":"2020","unstructured":"Chen H, Yao X, Di X, Zhang Y, Zhu H, Liu S, et al. MiR-450a-5p inhibits autophagy and enhances radiosensitivity by targeting dual-specificity phosphatase 10 in esophageal squamous cell carcinoma. Cancer Lett. 2020;483:114\u201326. https:\/\/doi.org\/10.1016\/j.canlet.2020.01.037.","journal-title":"Cancer Lett"},{"issue":"2","key":"13231_CR65","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","volume":"74","author":"IJ AP","year":"2022","unstructured":"AP IJ, Jacobson KA, Muller CE, Cronstein BN, Cunha RA. International Union of Basic and Clinical Pharmacology. CXII: Adenosine receptors: a further update. Pharmacol Rev. 2022;74(2):340\u201372. https:\/\/doi.org\/10.1124\/pharmrev.121.000445.","journal-title":"Pharmacol Rev"},{"key":"13231_CR66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2019.01.003","volume":"198","author":"EA Vecchio","year":"2019","unstructured":"Vecchio EA, White PJ, May LT. The adenosine A(2B) G protein-coupled receptor: recent advances and therapeutic implications. Pharmacol Ther. 2019;198:20\u201333. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.01.003.","journal-title":"Pharmacol Ther"},{"key":"13231_CR67","doi-asserted-by":"publisher","unstructured":"Campos-Contreras ADR, Gonzalez-Gallardo A, Diaz-Munoz M, Vazquez-Cuevas FG. Adenosine receptor A2B negatively regulates Cell Migration in Ovarian Carcinoma cells. Int J Mol Sci. 2022;23(9). https:\/\/doi.org\/10.3390\/ijms23094585.","DOI":"10.3390\/ijms23094585"},{"issue":"12","key":"13231_CR68","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1158\/0008-5472.CAN-19-3954","volume":"80","author":"G Vasiukov","year":"2020","unstructured":"Vasiukov G, Novitskaya T, Zijlstra A, Owens P, Ye F, Zhao Z, et al. Myeloid cell-derived TGFbeta Signaling regulates ECM deposition in Mammary Carcinoma via Adenosine-Dependent mechanisms. Cancer Res. 2020;80(12):2628\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3954.","journal-title":"Cancer Res"},{"issue":"1","key":"13231_CR69","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12072-019-10003-2","volume":"14","author":"J Liao","year":"2020","unstructured":"Liao J, Zeng DN, Li JZ, Hua QM, Xiao Z, He C, et al. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatol Int. 2020;14(1):80\u201395. https:\/\/doi.org\/10.1007\/s12072-019-10003-2.","journal-title":"Hepatol Int"},{"issue":"1","key":"13231_CR70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1248\/bpb.b23-00631","volume":"47","author":"M Oyama","year":"2024","unstructured":"Oyama M, Sakamoto M, Kitabatake K, Shiina K, Kitahara D, Onozawa S, et al. Involvement of cannabinoid receptors and Adenosine A2B receptor in enhanced Migration of Lung Cancer A549 cells Induced by gamma-Ray Irradiation. Biol Pharm Bull. 2024;47(1):60\u201371. https:\/\/doi.org\/10.1248\/bpb.b23-00631.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"13231_CR71","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1248\/bpb.b20-00654","volume":"44","author":"K Kitabatake","year":"2021","unstructured":"Kitabatake K, Kaji T, Tsukimoto M. Involvement of CD73 and A2B receptor in Radiation-Induced DNA damage response and cell Migration in Human Glioblastoma A172 cells. Biol Pharm Bull. 2021;44(2):197\u2013210. https:\/\/doi.org\/10.1248\/bpb.b20-00654.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"13231_CR72","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1006\/geno.1998.5539","volume":"54","author":"RM sBecker","year":"1998","unstructured":"sBecker RM, Darrow C, Zimonjic DB, Popescu NC, Watson MA, Fleming TP. Identification of mammaglobin B, a novel member of the uteroglobin gene family. Genomics. 1998;54(1):70\u20138. https:\/\/doi.org\/10.1006\/geno.1998.5539.","journal-title":"Genomics"},{"issue":"2","key":"13231_CR73","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/bjc.2013.315","volume":"109","author":"S Bellone","year":"2013","unstructured":"Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, et al. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. Br J Cancer. 2013;109(2):462\u201371. https:\/\/doi.org\/10.1038\/bjc.2013.315.","journal-title":"Br J Cancer"},{"issue":"3","key":"13231_CR74","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/annonc\/mdj109","volume":"17","author":"L Mercatali","year":"2006","unstructured":"Mercatali L, Valenti V, Calistri D, Calpona S, Rosti G, Folli S, et al. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. Ann Oncol. 2006;17(3):424\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdj109.","journal-title":"Ann Oncol"},{"issue":"5","key":"13231_CR75","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1309\/MMAC-TXT5-5L8Q-TKC1","volume":"121","author":"RJ Ouellette","year":"2004","unstructured":"Ouellette RJ, Richard D, Maicas E. RT-PCR for mammaglobin genes, MGB1 and MGB2, identifies breast cancer micrometastases in sentinel lymph nodes. Am J Clin Pathol. 2004;121(5):637\u201343. https:\/\/doi.org\/10.1309\/MMAC-TXT5-5L8Q-TKC1.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"13231_CR76","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3892\/ijo.2014.2316","volume":"44","author":"K Munakata","year":"2014","unstructured":"Munakata K, Uemura M, Takemasa I, Ozaki M, Konno M, Nishimura J, et al. SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance. Int J Oncol. 2014;44(5):1521\u20138. https:\/\/doi.org\/10.3892\/ijo.2014.2316.","journal-title":"Int J Oncol"},{"issue":"5","key":"13231_CR77","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/emboj\/21.5.1012","volume":"21","author":"S Halevi","year":"2002","unstructured":"Halevi S, McKay J, Palfreyman M, Yassin L, Eshel M, Jorgensen E, et al. The C. Elegans ric-3 gene is required for maturation of nicotinic acetylcholine receptors. EMBO J. 2002;21(5):1012\u201320. https:\/\/doi.org\/10.1093\/emboj\/21.5.1012.","journal-title":"EMBO J"},{"issue":"22","key":"13231_CR78","doi-asserted-by":"publisher","first-page":"12593","DOI":"10.1073\/pnas.93.22.12593","volume":"93","author":"KG sMiller","year":"1996","unstructured":"sMiller KG, Alfonso A, Nguyen M, Crowell JA, Johnson CD, Rand JB. A genetic selection for Caenorhabditis elegans synaptic transmission mutants. Proc Natl Acad Sci U S A. 1996;93(22):12593\u20138. https:\/\/doi.org\/10.1073\/pnas.93.22.12593.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"13231_CR79","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.neuroscience.2007.06.008","volume":"148","author":"EG Severance","year":"2007","unstructured":"Severance EG, Yolken RH. Lack of RIC-3 congruence with beta2 subunit-containing nicotinic acetylcholine receptors in bipolar disorder. Neuroscience. 2007;148(2):454\u201360. https:\/\/doi.org\/10.1016\/j.neuroscience.2007.06.008.","journal-title":"Neuroscience"},{"issue":"8","key":"13231_CR80","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1136\/jmedgenet-2015-103616","volume":"53","author":"S Sudhaman","year":"2016","unstructured":"Sudhaman S, Muthane UB, Behari M, Govindappa ST, Juyal RC, Thelma BK. Evidence of mutations in RIC3 acetylcholine receptor chaperone as a novel cause of autosomal-dominant Parkinson\u2019s disease with non-motor phenotypes. J Med Genet. 2016;53(8):559\u201366. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103616.","journal-title":"J Med Genet"},{"issue":"9","key":"13231_CR81","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1002\/hbm.22494","volume":"35","author":"JS Yokoyama","year":"2014","unstructured":"Yokoyama JS, Evans DS, Coppola G, Kramer JH, Tranah GJ, Yaffe K. Genetic modifiers of cognitive maintenance among older adults. Hum Brain Mapp. 2014;35(9):4556\u201365. https:\/\/doi.org\/10.1002\/hbm.22494.","journal-title":"Hum Brain Mapp"},{"key":"13231_CR82","doi-asserted-by":"publisher","first-page":"709669","DOI":"10.3389\/fcell.2021.709669","volume":"9","author":"G Chen","year":"2021","unstructured":"Chen G, Long J, Zhu R, Yang G, Qiu J, Zhao F, et al. Identification and validation of constructing the Prognostic Model with four DNA methylation-driven genes in pancreatic Cancer. Front Cell Dev Biol. 2021;9:709669. https:\/\/doi.org\/10.3389\/fcell.2021.709669.","journal-title":"Front Cell Dev Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13231-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13231-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13231-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T10:48:06Z","timestamp":1733395686000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13231-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13231"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13231-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1497"}}